[go: up one dir, main page]

ES8800604A1 - Un metodo para producir anticuerpos monoclonales - Google Patents

Un metodo para producir anticuerpos monoclonales

Info

Publication number
ES8800604A1
ES8800604A1 ES554209A ES554209A ES8800604A1 ES 8800604 A1 ES8800604 A1 ES 8800604A1 ES 554209 A ES554209 A ES 554209A ES 554209 A ES554209 A ES 554209A ES 8800604 A1 ES8800604 A1 ES 8800604A1
Authority
ES
Spain
Prior art keywords
mouse
host
associated antigen
tumor associated
lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES554209A
Other languages
English (en)
Other versions
ES554209A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES554209A0 publication Critical patent/ES554209A0/es
Publication of ES8800604A1 publication Critical patent/ES8800604A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE ANTICUERPOS MONOCLONALES. CONSISTE EN INMUNIZAR UN RATON U OTRO HOSPEDANTE ADECUADO CON UN ANTIGENO PURIFICADO DERIVADO DE UNA FUENTE DE TEJIDO HUMANO O DE UNA LINEA CELULAR HUMANA CANCEROSA; FUSIONARCELULAS DE BAZO DEL RATON U HOSPEDANTE ASI INMUNIZADO CON CELULAS DE MIELONA DE RATON; CULTIVAR LAS LINEAS CELULARES HIBRIDAS ASI FORMADAS EN UN MEDIO ADECUADO, SELECCIONAR Y CLONAR LINEAS Y RECUPERAR EL ANTICUERPO MONOCLONAL ASI OBTENIDO. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA LA DETECCION, EL DIAGNOSTICO Y EL TRATAMIENTO DEL CANCER EN SERES HUMANOS.
ES554209A 1985-04-22 1986-04-21 Un metodo para producir anticuerpos monoclonales Expired ES8800604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72620285A 1985-04-22 1985-04-22

Publications (2)

Publication Number Publication Date
ES554209A0 ES554209A0 (es) 1987-11-16
ES8800604A1 true ES8800604A1 (es) 1987-11-16

Family

ID=24917624

Family Applications (2)

Application Number Title Priority Date Filing Date
ES554209A Expired ES8800604A1 (es) 1985-04-22 1986-04-21 Un metodo para producir anticuerpos monoclonales
ES557680A Expired ES8900247A1 (es) 1985-04-22 1987-08-17 Un metodo de detecion y diagnostico de cancer empleando un nuevo antigeno asociado a un tumor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557680A Expired ES8900247A1 (es) 1985-04-22 1987-08-17 Un metodo de detecion y diagnostico de cancer empleando un nuevo antigeno asociado a un tumor.

Country Status (9)

Country Link
EP (1) EP0200464B1 (es)
JP (1) JPS61289897A (es)
AT (1) ATE79632T1 (es)
AU (2) AU599589B2 (es)
DE (1) DE3686438T2 (es)
DK (1) DK185086A (es)
ES (2) ES8800604A1 (es)
FI (1) FI87141C (es)
NO (1) NO170810C (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613590B2 (en) * 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
JPS63157995A (ja) * 1986-12-18 1988-06-30 Kyowa Hakko Kogyo Co Ltd 抗ヒト大腸癌単クロ−ン性抗体ａｃｃ−５７４
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
US5073493A (en) * 1987-05-29 1991-12-17 Ikuo Yamashina Monoclonal antibody nky13
JP2688824B2 (ja) * 1987-05-29 1997-12-10 郁男 山科 単クローン抗体ｎｋｙ１３
EP0328578B1 (en) * 1987-07-02 1996-05-08 Akzo Nobel N.V. Antigen recognized by mca 16-88
EP0397419A3 (en) * 1989-05-10 1991-04-03 Hybritech Incorporated Novel tumor-associated antigen, antibodies, compositions and uses therefor
DE69029270T2 (de) * 1989-09-15 1997-03-27 Genetic Systems Corp., Seattle, Wash. HYBRIDOMA CT43, DAS EIN ANTIKöRPER GEGEN EIN MUCINEPITOP VON DARMKREBS ERZEUGT
US20010055596A1 (en) * 2000-03-24 2001-12-27 Meagher Madeleine Joy Compositions and methods for therapy and diagnosis of colon cancer
US20120021444A1 (en) * 2008-12-18 2012-01-26 Eidia Co., Ltd. Method for diagnosis of cystic fibrosis using kl-6 levels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468457A (en) * 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
NZ212419A (en) * 1984-06-25 1988-08-30 Mucan Diagnostics Pty Ltd In vitro diagnostic test for detecting cancer cells producing mucin antigens
DK172686A (da) * 1985-04-22 1986-10-23 Hybritech Inc Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet

Also Published As

Publication number Publication date
ES557680A0 (es) 1989-05-16
DE3686438D1 (de) 1992-09-24
AU627084B2 (en) 1992-08-13
NO170810C (no) 1992-12-09
FI861692L (fi) 1986-10-23
ES554209A0 (es) 1987-11-16
AU5646986A (en) 1987-10-29
FI87141C (fi) 1992-12-10
DE3686438T2 (de) 1993-01-21
NO170810B (no) 1992-08-31
ATE79632T1 (de) 1992-09-15
DK185086A (da) 1986-10-23
FI861692A0 (fi) 1986-04-22
EP0200464A2 (en) 1986-11-05
JPS61289897A (ja) 1986-12-19
NO861577L (no) 1986-10-23
AU6556990A (en) 1991-01-17
FI87141B (fi) 1992-08-31
EP0200464A3 (en) 1988-05-04
DK185086D0 (da) 1986-04-22
EP0200464B1 (en) 1992-08-19
AU599589B2 (en) 1990-07-26
ES8900247A1 (es) 1989-05-16

Similar Documents

Publication Publication Date Title
ATE85652T1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DK2289A (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
DE68928857D1 (de) Monoklonale Antikörper, die mit Cachectin reagieren
ATE188708T1 (de) Antikörperderivate
NO913211D0 (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
ATE125626T1 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
ES8800604A1 (es) Un metodo para producir anticuerpos monoclonales
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
SE8700805D0 (sv) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
DK0454782T3 (da) Cancer-beslægtet haptaglobin (Hpr.)
NO168311C (no) Monoklonale antistoffer for humane ikke-smaacelle lungekarsinomer, cellelinjer som produserer disse samt diagnostisksett
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
DE3855280D1 (de) Von mca 16-88 erkanntes antigen
EP0143367A3 (en) Method for production of monoclonal antibodies for cancer diagnosis and therapy
ATE138200T1 (de) Das von mca-28a32 erkannte antigen
Lewis The role of circulating antibody in the control of metastases
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
EP0278160A3 (en) Human monoclonal anti cancer antibodies, hybridoma cell lines producing them and their uses
JPS6444856A (en) Anti-cancer antigen anti-serum
DK182188A (da) Humant tumorassocieret antigen
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου